ReviewClinical and translational radiation oncology2023
The role of image-guided radiotherapy in prostate cancer: A systematic review and meta-analysis.
Review in Clinical and translational radiation oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Impact of Hydrogel Spacer on Radiation Proctitis After Prostate Cancer Radiation Therapy: A Large-Scale Claims Database Analysis.Advances in radiation oncology · 2026Article
- Moderately hypofractionated intensity-modulated radiation therapy for intermediate- or high-risk prostate cancer: five-year results from a single-institution study in Japan.International journal of clinical oncology · 2026Article
- Impact of image-guided radiation therapy with intraprostatic seeds on long-term toxicity in prostate cancer patients undergoing risk-adapted intensification therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Implementation of an AI-Driven Workflow for Daily Dose Reconstruction in Prostate Cancer Radiotherapy.Cancers · 2026Article
- Pathological complete response to perioperative treatment with darolutamide plus ADT in locally advanced prostate cancer without PTEN or RB1 loss: a case report.Frontiers in pharmacology · 2026Article
- Anatomically informed deep learning framework for generating fast, low-dose synthetic CBCT for prostate radiotherapy.Scientific reports · 2025Article
- Predictive Factors for Gastrointestinal and Genitourinary Toxicities in Prostate Cancer External Beam Radiotherapy: A Scoping Review.Diagnostics (Basel, Switzerland) · 2025Review
- Outcomes and Toxicities After Treatment for Men Diagnosed With Localized Prostate Cancer in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis.Advances in radiation oncology · 2025Review
- Hydrogel technologies in andrology: advances in research and prospective applications.Frontiers in pharmacology · 2025Review
- Immune effects of α and β radionuclides in metastatic prostate cancer.Nature reviews. Urology · 2024Review
- Radiation-Induced Hemorrhagic Cystitis in Prostate Cancer Survivors: The Hidden Toll.Medicina (Kaunas, Lithuania) · 2024Article
- Clinical and Dosimetric Comparison Between Non-image Guided Radiation Therapy and Fiducial-Based Image Guided Radiation Therapy With or Without Reduced Margin in Intensity Modulated Radiation Therapy for Prostate Cancer.Advances in radiation oncology · 2024Article
- The impact of plan complexity on calculation and measurement-based pre-treatment verifications for sliding-window intensity-modulated radiotherapy.Physics and imaging in radiation oncology · 2024Article
- MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study.Clinical and translational radiation oncology · 2024Article
- A Single-Institution Prospective Study To Evaluate the Safety and Efficacy of Real- Time Image-Gated Spot-Scanning Proton Therapy (RGPT) for Prostate Cancer.Advances in radiation oncology · 2024Article
- Impact of prostate position-based image-guidance in intensity-modulated radiation therapy for localized prostate cancer.International journal of clinical oncology · 2024Article
- Electromagnetic Transmitter-Based Prostate Gating for Dose-Escalated Linac-Based Stereotactic Body Radiation Therapy: An Evaluation of Intrafraction Motion.Current oncology (Toronto, Ont.) · 2024Article
- Impact of technological advances in treatment planning, image guidance, and treatment delivery on target margin design for prostate cancer radiotherapy: an updated review.The British journal of radiology · 2024Review
- The Current Trend of Radiation Therapy for Patients with Localized Prostate Cancer.Current oncology (Toronto, Ont.) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Image-guided radiotherapy (IGRT) has gradually been widely promoted in clinical procedure. However, there has been no consensus on the effects of IGRT on toxicity and survival, and no clear level 1 evidence has even been promulgated. Methods: Medline, EMBASE, PubMed, Cochrane databases and ClinicalTrials.gov were searched for studies comparing IGRT vs non-IGRT or higher frequency IGRT vs lower frequency IGRT during prostate radiotherapy, indexed from database inception to April 2022. Results: The review included 18 studies (3 randomized clinical trial and 15 cohort studies) involving 6521 men, with a median duration of patient follow-up of 46.2 months in the IGRT group vs 52.7 months in the control group. The Conclusions: For men receiving prostate radiotherapy, IGRT was associated with an improvement in biochemical tumor control and a reduction in GI and acute GU toxicity, but did not significantly improve 5-year OS or increase 5-year SCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.